We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Paul Hudson is meeting investors to explain multibillion-euro push to get drug candidates to market
Evobrutinib would have more than compensated for falling sales from German group’s existing medicines
Evobrutinib failed to reduce relapse rates compared with teriflunomide, produced by rival Sanofi
Wuxi Biologics is likely to miss its original sales target for the year by about $400mn
Pharma group behind blockbuster drug wants to supersize its market impact
Members of the company’s founding family fight to uphold protections from $6bn opioid bankruptcy settlement in closely watched case
The Swiss pharma group needs to settle investor jitters with its latest acquisition
Swiss pharmaceutical group is under pressure to strengthen its pipeline of medicines
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Group plans to refocus on 30 core brands
Decision is setback for US drugmaker looking to increase sales after pandemic
Key drugs are due to lose exclusivity in the important US market in 2027
Innovative models can drive funding for research on neglected, less survivable diseases
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup
Vaccine recipient claims he suffered side effect of severe blood clot
How pension funds’ investments have impacted the London Stock Exchange
Growth cap on UK’s health service branded drugs bill will rise to 4% from 2027
German group says prospective blockbuster asundexian failed to demonstrate efficacy
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
Regulator authorises treatment for sickle cell disease and beta thalassaemia
T-Therapeutics hopes to use genetically engineered rodents and machine learning to discover drugs
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
International Edition
